|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
 |
Singapore and Boulogne-Billancourt, France, March 22nd 2007, Maccine Pte Ltd and Porsolt & Partners Pharmacology today announced that they have entered into a strategic co-marketing agreement. Under the terms of the agreement the two firms will promote their collective preclinical contract research service lines to the global pharmaceutical and biotech industry. Dr Mark Duxon, CEO of Maccine, commented on the move, “We are delighted to be working alongside Porsolt & Partners Pharmacology, who have been leaders in their in vivo pharmacology domains for over 20 years. Maccine's provision of safety and efficacy pharmacology services is completely complementary so this was a natural step and very much in line with our principle of offering quality work throughout the early development process. “Both Companies share the same guiding principle of excellence in a focused research area. Smart outsourcing is a prerequisite to a successful path to the clinic. This partnership presents the industry with a collective portfolio of innovative and quality services across the full range of research species” said Duxon. Dr Martine Lemaire, Senior Director of Scientific & Business Development at Porsolt & Partners Pharmacology said “We are excited about this agreement with Maccine and the synergies it will bring to our business. With more than 20 years of experience, we recognize that providing a full package of flexible and tailored quality solutions is the key to satisfaction of our clients. Porsolt & Partners Pharmacology is committed to staying at the forefront of our field of acknowledge expertise and Maccine’s expertise and positioning with primate research will extend our range of services and enable us to meet the needs of our sponsors.” About Maccine For further information please contact: media@maccine.com About Porsolt & Partners Pharmacology For further information please contact: Website: www.porsolt.com
|